Literature DB >> 17332342

Insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human mammary cancer cells.

Ozlem Dalmizrak1, An Wu, Jia Chen, Hongzhi Sun, Fransiscus E Utama, Diana Zambelli, Thai H Tran, Hallgeir Rui, Renato Baserga.   

Abstract

Although originating from a human breast cancer, BT-20 cells do not form colonies in soft agar. BT-20 cells do not express insulin receptor substrate-1 (IRS-1), which is known to promote both normal and abnormal growth and to inhibit differentiation. Stable expression of IRS-1 confers to BT-20 cells the ability to form colonies in soft agar. BT-20 cells form tumors in xenografts in mice, but the size of tumors is twice as large when the cells express IRS-1. The increased transformed phenotype is characterized by occupancy of the rDNA and cyclin D1 promoters by IRS-1 and the activation of the cyclin D1, c-myc, and rDNA promoters. In addition, the retinoblastoma protein, which is detectable in the rDNA promoter of quiescent BT-20/IRS-1 cells, is replaced by IRS-1 after insulin-like growth factor-I stimulation. Our results indicate that in BT-20 human mammary cancer cells, expression of IRS-1 activates promoters involved in cell growth and cell proliferation, resulting in a more transformed phenotype. Targeting of IRS-1 could be effective in inhibiting the proliferation of mammary cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332342     DOI: 10.1158/0008-5472.CAN-06-3954

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Therapeutic destruction of insulin receptor substrates for cancer treatment.

Authors:  Hadas Reuveni; Efrat Flashner-Abramson; Lilach Steiner; Kirill Makedonski; Renduo Song; Alexei Shir; Meenhard Herlyn; Menashe Bar-Eli; Alexander Levitzki
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

2.  Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through blocking autophagic degradation of dishevelled2.

Authors:  Yongtao Geng; Yanfang Ju; Fangli Ren; Ying Qiu; Yasuhiko Tomita; Miki Tomoeda; Mioka Kishida; Yinyin Wang; Lian Jin; Fuqin Su; Chunhong Wei; Baoqing Jia; Yi Li; Zhijie Chang
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

3.  Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.

Authors:  Hao Cai; Ruth S Everett; Dhiren R Thakker
Journal:  Br J Pharmacol       Date:  2019-06-26       Impact factor: 8.739

4.  Depletion of insulin receptor substrate 2 reverses oncogenic transformation induced by v-src.

Authors:  Hong-zhi Sun; Lin Xu; Bo Zhou; Wei-jin Zang; Shu-fang Wu
Journal:  Acta Pharmacol Sin       Date:  2011-05-02       Impact factor: 6.150

5.  Growth of v-src-transformed cells in serum-free medium through the induction of growth factors.

Authors:  Tiziana Deangelis; Andrew Quong; Andrea Morrione; Renato Baserga
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

6.  Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.

Authors:  Anurag Purushothaman; Stephen K Babitz; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

Review 7.  Insulin receptor substrates (IRSs) and breast tumorigenesis.

Authors:  Bonita Tak-Yee Chan; Adrian V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

8.  Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma.

Authors:  Katarzyna Urbanska; Paola Pannizzo; Adam Lassak; Elisa Gualco; Eva Surmacz; Sidney Croul; Luis Del Valle; Kamel Khalili; Krzysztof Reiss
Journal:  J Cell Physiol       Date:  2009-05       Impact factor: 6.384

9.  A novel myogenic function residing in the 5' non-coding region of Insulin receptor substrate-1 (Irs-1) transcript.

Authors:  Hikaru Nagano; Naoko Yamagishi; Chisato Tomida; Chiaki Yano; Kana Aibara; Shohei Kohno; Tomoki Abe; Ayako Ohno; Katsuya Hirasaka; Yuushi Okumura; Edward M Mills; Takeshi Nikawa; Shigetada Teshima-Kondo
Journal:  BMC Cell Biol       Date:  2015-03-11       Impact factor: 4.241

10.  SH2B1 promotes epithelial-mesenchymal transition through the IRS1/β-catenin signaling axis in lung adenocarcinoma.

Authors:  Shaoqiang Wang; Yuanda Cheng; Yang Gao; Zhiwei He; Wolong Zhou; Ruimin Chang; Zhenzi Peng; Yingying Zheng; Chaojun Duan; Chunfang Zhang
Journal:  Mol Carcinog       Date:  2018-02-20       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.